AACR 2026 Showcases Cellular Therapies and Complex Immunotherapies for Solid Tumors and Blood Cancers

The American Association for Cancer Research Annual Meeting 2026 (AACR 2026) featured a clinical trials plenary session focused on cellular therapies and complex immunotherapies. This gathering in San Diego highlighted how researchers are refining immune-based treatments to overcome the limitations of conventional oncology protocols. The presentations demonstrated engineering techniques designed to tackle immune exhaustion, target complex antigens, and treat precursor conditions before they develop into active malignancies.

Scientists shared four clinical studies tracking progress across various tumor types. These included an investigational CAR T-cell intervention for a multiple myeloma precursor condition and a first-in-human trial using a modified natural killer cell receptor platform for solid tumors. Researchers also detailed efficacy data combining a targeted costimulatory agent with a T-cell engager in colorectal cancer, along with a novel mRNA cancer vaccine showing clinical responses in melanoma.

The Difficult Challenge of Precursor Myeloma

Multiple myeloma typically arises from precursor conditions such as smoldering multiple myeloma (SMM). According to presenter Omar Nadeem from the Dana-Farber Cancer Institute, nearly half of these high-risk patients progress to active disease within two years. This rapid progression brings debilitating complications such as bone lesions, kidney failure, anemia, and general frailty. Historically, physicians relied on active monitoring through regular lab tests and imaging. Patients typically began therapy only after they developed organ damage or other active symptoms. While some individuals accessed experimental treatments through clinical trials, these options remained largely inaccessible outside major cancer centers.

In November 2025, the U.S. FDA approved the CD38-targeted monoclonal antibody daratumumab and hyaluronidase as the first therapeutic for high-risk SMM. Although this treatment reduced disease progression by 51%, patients must undergo regular administrations for up to three years. Furthermore, Nadeem pointed out that the pivotal trial did not evaluate minimal residual disease (MRD). This gap leaves patients potentially vulnerable to long-term disease relapse and highlights the ongoing need for more definitive treatments.

Intercepting the Disease Early with CAR T-cell Therapy

To intercept this disease earlier, researchers developed ciltacabtagene autoleucel, a BCMA-directed chimeric antigen receptor T-cell therapy, in this specific population and initiated the phase 2 CAR-PRISM clinical trial to evaluate its efficacy and safety. The trial enrolled 20 patients who had not previously received standard myeloma therapies. The research team hypothesized that administering these engineered cells during the smoldering phase would leverage a more robust immune system and a less complex tumor burden. Patients with bone marrow plasma cell infiltration exceeding 40% were excluded from the trial since there was no induction or bridging therapy administered in this study and these patients may be more likely to experience toxicities.

Based on the results presented by Dr. Nadeem during AACR 2026, all 20 participants achieved MRD negativity at the deepest measurable level within two months following the single infusion of CAR-T cells. The patients maintained this disease-free status at a median follow-up of 15.3 months, and investigators observed zero instances of disease progression or death. The safety profile proved manageable for an early intervention. All participants experienced only low-grade cytokine release syndrome, avoiding the grade 3 or 4 immune reactions frequently associated with later-line applications. Seven patients developed mild neurological symptoms, prompting researchers to optimize the protocol with dose adjustments and prophylactic medication. These findings suggest that moving advanced cellular therapies into earlier treatment lines could redefine the standard of care for high-risk precursor conditions.

A Novel Receptor Design for Solid Tumors

Solid tumors consistently resist conventional CAR T-cell therapies due to dense physical barriers and immunosuppressive microenvironments that trigger rapid T-cell exhaustion. To overcome these persistent biological hurdles, Janos L. Tanyi from the University of Pennsylvania Abramson Cancer Center, presented initial data from the STAR-101 phase 1 dose-escalation trial. The study evaluated SynKIR-110, an investigational cellular therapy developed by Verismo Therapeutics. This treatment specifically targets mesothelin, a cell-surface protein abundant in aggressive malignancies such as ovarian cancer, mesothelioma, and cholangiocarcinoma. Because healthy tissues express mesothelin at very low levels, the protein serves as an ideal target for precision immunotherapy.

Unlike traditional single-chain CAR T-cells that often suffer from premature exhaustion, SynKIR-110 utilizes a multi-chain killer immunoglobulin-like receptor that scientists modeled directly after natural killer (NK) cells. The platform physically separates the tumor-binding domain from the internal signaling mechanism using a specialized DAP12 adapter protein. This split-signaling approach prevents the constant tonic signaling that typically causes engineered T-cells to burn out before reaching the tumor bed. Consequently, the modified cells maintain their functional capacity and persistence much longer when infiltrating hostile tumor microenvironments.

The early clinical results demonstrated a manageable safety profile and antitumor activity in nine heavily pre-treated patients who had exhausted standard therapeutic options. Blood analyses revealed that the engineered cells expanded rapidly in the systemic circulation, reaching peak concentrations roughly seven days following the infusion. The researchers observed zero immune effector cell-associated neurologic events and only low-grade cytokine release syndrome. Four of the nine patients exhibited measurable tumor responses. One patient experienced a 47% reduction in tumor volume, while another maintained a partial response through six months of continuous follow-up. Moving forward, the research team will continue dose escalation to establish the optimal treatment parameters for larger clinical evaluations.

Amplifying Immune Responses in Colorectal Cancer

Microsatellite-stable metastatic colorectal cancer historically resists immunotherapy because these tumors typically lack inflammatory immune cells. Oncologists commonly refer to these malignancies as “cold tumors”. Ignacio Melero from the Clínica Universidad de Navarra in Spain presented data from a phase 1b trial investigating a dual-targeting strategy designed to convert these non-inflammatory tumors into immunotherapy-responsive environments. The trial evaluated cibisatamab, a bispecific antibody that physically links T-cells to the carcinoembryonic antigen (CEA) expressed on tumor cells. To maximize the immune response, the researchers combined this T-cell engager with FAP-4-1BBL, a targeted costimulatory molecule.

FAP-4-1BBL binds to fibroblast activation protein (FAP) located on the tumor stroma. Once bound, it delivers a critical 4-1BB activation signal specifically to T-cells residing within the tumor microenvironment. While cibisatamab effectively brings T-cells to cancer cells, optimal activation and sustained T-cell survival require this secondary costimulatory signal. In the past, delivering 4-1BB signals systemically caused significant liver toxicity. However, this tumor-targeted combination therapy amplified T-cell activity locally without triggering widespread systemic side effects. Tissue biopsies confirmed that the combination treatment significantly increased the infiltration of actively dividing CD8-positive T-cells directly into the tumor mass.

The trial enrolled heavily pre-treated patients who had exhausted standard treatment options. Among 51 evaluable patients across various dose levels, the overall response rate reached 17.6%, and the disease control rate achieved 50.9%. The efficacy proved particularly pronounced in the highest weekly dose cohorts. In this group, four out of eleven patients achieved a partial response, translating to a 36.4% response rate. Additionally, researchers observed that early reductions in circulating tumor DNA strongly correlated with improved clinical outcomes. Most adverse events were manageable, with patients primarily experiencing low-grade cytokine release syndrome that resolved with standard supportive care.

Deploying mRNA Technology Against Advanced Melanoma

Moderna expanded the application of its messenger RNA technology beyond infectious diseases into frontline oncology. Pavlina Spiliopoulou from the University of Glasgow presented results from the phase 1/2 mRNA-4359-P101 study. The clinical trial evaluated the investigational cancer antigen therapy mRNA-4359 in combination with the checkpoint inhibitor pembrolizumab (Keytruda) for patients with previously untreated advanced or metastatic melanoma.

mRNA-4359 encodes epitopes of two specific proteins, PD-L1 and IDO1, which typically suppress immune responses within the tumor microenvironment. The vaccine trains the immune system to recognize and eliminate both the tumor cells and the immunosuppressive cells shielding the malignancy. This dual mechanism actively rebalances the tumor environment into an immune-permissive state that supports sustained antitumor activity.

The combination therapy produced clinical responses in the initial patient cohort. Out of 12 evaluable participants, the treatment had an overall response rate of 83%. Two patients achieved a complete response, while eight others attained a partial response. The disease control rate reached 92%, with a median time to response of six weeks. Notably, these clinical responses occurred across various baseline categories of tumor PD-L1 expression. Translational data confirmed that the treatment consistently activated antigen-specific T cells across the patient group.

The U.S. FDA recently granted Fast Track designation for this specific therapeutic combination based on these early clinical signals. The regimen maintained a consistent safety profile and introduced no new immune-related adverse events compared to standard pembrolizumab monotherapy. Researchers plan to expand the patient cohorts to further validate these efficacy signals and refine the optimal dosing strategy.

Paving the Way for Next-Generation Immunology

The clinical trial updates from AACR 2026 underscore an evolution in the field of oncology. Medical researchers are moving beyond generalized immune stimulation toward targeted and precision-engineered cellular interventions. By adapting NK cell architectures, localizing costimulatory signals, and deploying customized mRNA vaccines, developers are steadily overcoming the biological barriers that historically protected solid tumors and aggressive blood cancers.

The above-mentioned early-phase studies provide a solid clinical foundation for future investigations. As these platforms advance into larger randomized trials, they hold the potential to improve survival rates and reduce the side effects typically associated with conventional treatments. The continued refinement of complex immunotherapies ensures that patients facing refractory or precursor malignancies will soon have access to more practical therapeutic options.

Author

Richard Chau